Updated: Oct 19
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
This case follows Nini (alias), a young girl whose B-ALL relapsed after initial chemotherapy, and her mother's decision to pursue CD19 CAR-T therapy bridged to a haploidentical stem cell transplant — using herself as a 60%-matched donor, her only viable option as a single parent — at a top hematology hospital in China.
For international families facing a similarly difficult relapse, especially where a fully matched donor isn't available, ChinaCureLink can help evaluate access to this same combined treatment approach.
Key Takeaways |
|
Patient Background
Nini was diagnosed with B-cell acute lymphoblastic leukemia in 2020, initially classified as medium-risk based on her white blood cell count at diagnosis. She completed two years of standard chemotherapy at a local hospital and appeared stable after stopping treatment. In 2023, a routine bone marrow check revealed the leukemia had returned.
Facing conflicting opinions about her daughter's prognosis, her mother sought a second opinion and was referred to a top hematology hospital in China, known as a leading center for treating difficult and relapsed leukemia cases. On re-evaluation, doctors reclassified Nini's original diagnosis as high-risk rather than medium-risk, given how elevated her white blood cell count had actually been at the outset — a distinction that may have contributed to her relapse.
The Care Team and Approach
On arrival, Nini's bone marrow showed leukemia blasts as high as 95–96%. After two weeks of chemotherapy, that figure had only dropped to around 80%, and testing revealed central nervous system involvement — a complication that raised the risk of a more severe and prolonged reaction to CAR-T therapy.
Director Sun Lei (pseudonym) recommended CD19 CAR-T cell therapy, followed by bridging to an allogeneic stem cell transplant to consolidate the response and improve long-term survival. Given the central nervous system involvement, the care team warned Nini's mother in advance that she might experience a more intense and longer-lasting cytokine release reaction than typical CAR-T patients.
That warning proved accurate: shortly after infusion, Nini developed a high fever accompanied by a seizure-like reaction. Her mother stayed at her bedside around the clock through the difficult days that followed, with the care team available even through a national holiday period when staffing was reduced. Nini's condition stabilized, and CAR-T therapy successfully cleared her measurable residual disease (MRD) — a result her care team explained was not a cure on its own, but the necessary window needed to move forward safely into transplant, ideally within 15 to 40 days.
With no fully matched donor available, Nini's mother underwent testing as a potential donor and was found to be a 60% HLA match — not an ideal match, but her only option as a single parent. The care team explained that donor stem cell quality mattered more to transplant success than the degree of genetic match, which helped inform the family's decision to proceed. The transplant itself went relatively smoothly, with only mild oral and skin graft-versus-host effects and no serious rejection.
Treatment Timeline/ Process
Before Treatment
2020: Diagnosed with B-cell acute lymphoblastic leukemia, initially classified as medium-risk; completed two years of standard chemotherapy at a local hospital
2023: Leukemia relapsed, confirmed by bone marrow biopsy
At the Hospital
Re-evaluated and reclassified as high-risk; bone marrow showed 95–96% leukemia blasts
After two weeks of chemotherapy, blasts remained around 80%, with central nervous system involvement identified
Underwent CD19 CAR-T cell infusion; developed high fever and a seizure-like reaction shortly afterward, closely managed by the care team
CAR-T therapy cleared measurable residual disease (MRD), opening a window to proceed to transplant
Underwent a haploidentical stem cell transplant with her mother as a 60%-matched donor, within the recommended 15-to-40-day window after CAR-T
Experienced only mild oral and skin graft-versus-host effects during recovery, with no serious rejection
Outcome
Nini's transplant recovery was closely managed through minor complications — including a platelet-related nosebleed and a low-potassium-related bout of vomiting — each resolved with her care team's guidance. Six months after transplant, she and her mother returned home, and within about a year of starting treatment, Nini had fully returned to normal life: back in school, recovering well, and even taking part in creative and charitable activities she'd taken up during her recovery, including painting and baking. Her mother returned to work as well, describing the experience as one that ultimately made them both stronger.
How ChinaCureLink Can Help International Patients to Access This Treatment
Relapsed B-ALL, particularly with central nervous system involvement or without a fully matched transplant donor available, requires exactly the kind of coordinated, multi-step treatment Nini received — CAR-T therapy bridged carefully into a haploidentical transplant. ChinaCureLink helps international families in a similar position get a specialized case review and connects them with hospitals in China experienced in CAR-T-to-transplant protocols, coordinating medical record translation, donor evaluation, hospital matching, and every logistical step from first inquiry through treatment and long-term follow-up.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
What happens if there's no fully matched donor available for a stem cell transplant?
A haploidentical (half-matched) donor, often a parent, can be a viable option when a fully matched donor isn't available. Transplant success depends heavily on the quality of the donor's stem cells and careful post-transplant management, not solely on the degree of genetic match.
Why would a child need both CAR-T therapy and a stem cell transplant?
CAR-T therapy can clear measurable residual disease and create a window of safety, but it isn't always considered a standalone cure for high-risk or relapsed cases. Bridging to a transplant afterward is often recommended to consolidate the response and improve long-term survival, particularly in complex cases.
How can international families access CAR-T and transplant treatment for relapsed pediatric leukemia in China?
Access typically starts with a case review, where medical records, pathology, and prior treatment history are submitted for evaluation, along with donor testing if a family member may be eligible. ChinaCureLink coordinates this process and helps match families with hospitals experienced in combined CAR-T and transplant protocols.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This account reflects one patient's individual experience, which will vary by case, diagnosis stage, and other clinical factors. ChinaCureLink facilitates access to hospitals and treatment coordination — we do not provide medical care ourselves, and this content is not medical advice. Patients and families should consult a qualified pediatric hematologist-oncologist before making treatment decisions.
